Grant, Call number PAR-25-184
Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required)
National Institutes of Health
- , Add deadline: choose a calendar
- Institution applies
- Psychiatry, Clinical Pharmacology and
About
This phased award supports early clinical trials of drugs or neuromodulation devices for mental disorders. Teams study target engagement and clinical response, with an initial R61 phase and a possible transition to R33 support.
Topics
- Mental Disorders, search World Wide
- clinical trials, search World Wide
- neuromodulation devices, search World Wide
- target engagement, search World Wide
- clinical response, search World Wide
- R61/R33, search World Wide
- R61 phase, search World Wide
- R33 support, search World Wide
- Early Stage Testing, search World Wide
Eligibility
Covers: The announcement provides phased R61/R33 research support.
Eligible organizations based outside the US may apply.
Eligible organizations include universities, nonprofit research organizations and other categories specified in the announcement. Eligible organizations based outside the US may apply.
Source: simpler.grants.gov